API | fosravuconazole

fosravuconazole Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Fosravuconazole is a triazole antifungal agent. In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail. It is a prodrug that is converted into ravuconazole. ^Wikipedia

Chemistry

SMILES: C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F
InChIKey: SYTNEMZCCLUTNX-NPMXOYFQSA-N
Mol. Mass: 547.48
ALogP: 4.33 Partition coefficient
ChEMBL Molecule:
fosravuconazole

More Chemistry

Pharmacology

Mechanism of Action:
- Lanosterol 14-alpha demethylase (Candida albicans (strain SC5314 / ATCC MYA-2876) (Yeast)) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

fosravuconazole

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Mycetoma (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue